Latest News

Research Update End-yr 2 CHF 02528: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases

Diagnostic tests based on the detection of DNA from harmful organisms in clinical samples have revolutionized veterinary medicine in the last decades. Currently, diagnostic panels for several vectorborne diseases (VBDs) are available through universities and private labs in the USA and abroad. However, the vast majority of results from sick dogs are negative, which frustrates veterinarians and dog owners trying to reach a definitive diagnosis.

Continue reading “Research Update End-yr 2 CHF 02528: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”

Research Update Mid-year 4 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma

Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Recently, advances in the understanding of human lymphomas have focused on the area of epigenetics.

Continue reading “Research Update Mid-year 4 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma”

Research Update End-yr 1 CHF 02651: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling

Canine atopic dermatitis (CAD) is a common allergic skin disease of dogs with a strong genetic basis. Evidence from human studies suggests that several variants of AD exist with different mechanisms and responses to treatment. Current diagnosis of CAD requires time-consuming procedures that involve a considerable cost to the owner. Therefore, new approaches to identify molecular markers that can help with better diagnosis and management of the disease are warranted. In this study, we are using our tailored methodology for lipid biomarker discovery in CAD.

Continue reading “Research Update End-yr 1 CHF 02651: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling”

Research Update Mid-year 3 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy

The preparations for the CBD epilepsy study were started in December 2018, including hiring a fulltime research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; therefore, we are on track with 54 patients in 2 1/2 years.

Continue reading “Research Update Mid-year 3 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”

Research Update Mid- and End-yr 1 CHF 02643-A: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity

Initial studies on cytotoxicity by the research team show that CBD has cytotoxic activity on a variety of canine cancer cell lines at modest concentrations in the laboratory. These effects cause apoptosis, or programmed cell death, within a very short time frame, suggesting a discrete mechanism.

Continue reading “Research Update Mid- and End-yr 1 CHF 02643-A: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”

Research Update End-year 6 CHF 01760-T: Use of Gene Therapy to Treat Dilated Cardiomyopathy

Dilated cardiomyopathy (DCM) is the second most common cause of heart disease in dogs, and medical management of the secondary signs is the only therapeutic option. The outcome for affected dogs depends on the stage of disease and the breed. Once diagnosed, dogs typically exhibit rapid and uniform progression to congestive heart failure (CHF), with most living less than 6 months.

Continue reading “Research Update End-year 6 CHF 01760-T: Use of Gene Therapy to Treat Dilated Cardiomyopathy”

Research Update End-yr 1 CHF 02661: Investigation into Diet-Associated Dilated Cardiomyopathy in Dogs

The study titled “Investigation into Subclinical Diet-Associated Dilated Cardiomyopathy in Four Dog Breeds” is progressing on schedule. Enrollment for the first part of the study is at approximately 85%. We are aiming to finish enrollment by late spring/early summer, after which time we will concentrate on data collation and statistical analysis for the first part of the study.

Continue reading “Research Update End-yr 1 CHF 02661: Investigation into Diet-Associated Dilated Cardiomyopathy in Dogs”